News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Renishaw plc Release: Official Opening of New Facilities for Ground Breaking Molecular Diagnostics Company


9/2/2010 1:53:48 PM

Glasgow, Scotland, 2 September 2010 Renishaw Diagnostics Ltd, a world leading provider of trace level detection technologies based on the exploitation of Surface Enhanced Raman Spectroscopy (SERS) and Surface Enhanced Resonance Raman Scattering (SERRS) for clinical research and molecular diagnostics applications, today held its official opening of expanded premises on the Nova Technology Park.

The company (previously known as D3 Technologies) first moved into 3000sq.ft. custom-built laboratory and office space on the technology park in December 2007. Renishaw Diagnostic’s success in molecular diagnostics development with its clinical research collaborators coupled with its comprehensive business strategy required expanded facilities for an increased number of research and commercial staff.

The Opening Ceremony was performed by Sir David McMurtry, Renishaw’s Chairman & Chief Executive, and attended by Renishaw staff from across the UK as well as representatives from Scottish Enterprise, Scottish Development International, the Scottish Parliament and Nexxus, central Scotland’s life sciences network.

Renishaw Diagnostic’s CEO, David Burns, said, “I am delighted to welcome so many people to our new premises to see the facilities and to meet our highly skilled and dedicated staff. Renishaw Diagnostics will launch its first products into the molecular diagnostics market next year and we plan to become a major supplier of multiplexed molecular diagnostic systems for infectious diseases. This will allow clinicians to diagnose and treat more quickly.”

Lena Wilson, Chief Executive of Scottish Enterprise, said, "Renishaw Diagnostics is already showing huge promise in the field of molecular diagnostics and its expansion at Nova Technology Park is another big boost for Scotland’s world-leading life sciences industry.

“RSA funding is one of the key tools we can use to encourage both indigenous and foreign companies to invest in Scotland and we are thrilled that this funding has enabled Renishaw to invest in its Scottish base and create new jobs for Scotland.

“Renishaw Diagnostics is exactly the type of ambitious, growing and sustainable enterprise that Scotland needs more of, and we look forward to working closely with the team to help them realise their ambitious plans for growth.”

About Renishaw Diagnostics Ltd

Renishaw Diagnostics Ltd, formerly D3 Technologies Ltd, was a Strathclyde University spin-out before being acquired by the Renishaw Group, which is a leading global supplier of engineering technologies, medical devices and Raman spectroscopy systems. It is focused on developing and commercialising its first in vitro diagnostic (IVD) and clinical research products, with the goal of establishing Renishaw Diagnostics as the premium provider of automated, multiplex, high sensitivity molecular diagnostics products for the detection of human infectious diseases. The Company is based in Glasgow, Scotland, and further information is available at www.renishawdiagnostics.com.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES